Enuresis, NocturnalNCT07028645
Uroflowmetry and Nocturnal Enuresis
An observational study of Enuresis, Nocturnal, run by Furkan Adem Canbaz at 1 site in Turkey (Türkiye).
Trial summary
This study will evaluate the uroflowmetry parameters of patients which were treated for enuresis. Read more about this study
- Who is it for?
- Ages 5 to 17 years
- Conditions the study is for
- Enuresis, Nocturnal
- What is being tested?
- desmopressin melt form 120 μg, Desmopressin lyophilisate (Melt) and Propiverine tablet
- Type of treatment
- Pill or oral medicine
- How many people
- 100 participants
- Where
- 1 siteTurkey (Türkiye)
- Study dates
- 20 Aug 2022to 30 Dec 2025
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 5 to 17 years
- All sexes
- No healthy volunteers
- Child
Study population: Patients who were treated for enuresis in pediatric urology clinic of Sancaktepe Sehit Prof Dr Ilhan Varank Training and Research Hospital
Who may be able to join
- Presence of enuresis nocturna
- Patients who have uroflowmetry test
Who cannot join
- Presence of lower urinary tract symptoms
- Presence of anatomical or neurological problems
- Patients with missing data
Trial locations and contacts
1 site in 1 country.
Turkey (Türkiye)1 site
Sancaktepe Sehit Prof dr Ilhan Varank Training and Research Hospital
Istanbul, Kadikoy, 34000
About this study
Official title: Is Uroflowmetry Useful in Assessing Response to Pharmacological Treatment in Enuresis
This study will evaluate the uroflowmetry parameters of patients which were treated for enuresis.
Read the detailed description
A total of approximately 100 patients with enuresis will be evaluated retrospectively. Uroflowmetry parameters of these patients will be evaluated. For this purpose, patients will be divided to mainly three groups according to the treatment choices.
- Conditions
- Enuresis, Nocturnal
- Being tested
- desmopressin melt form 120 μg, Desmopressin lyophilisate (Melt), Propiverine tablet
- Keywords
- Uroflowmetry, Enuresis
- Medical subject headings
- Nocturnal Enuresis, Enuresis
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
desmopressin melt form 120 μgDrug
Desmopressin 120 mcg will be used frist-line drug in the treatment of enuresis.
Desmopressin lyophilisate (Melt)Drug
Desmopressin 240 mcg will be used for the patients who have not responsive to desmopressin 120 mcg.
Propiverine tabletDrug
Propiverine (a dose of 0.8 mg/ kg) will be used for the patients who have -response to treatment with desmopressin 240 mcg
| Study group | Role | What they receive |
|---|---|---|
| Desmopressin 120mcg | Patients treated with desmopressin 120 mcg Receives: Drug: desmopressin melt form 120 μg | |
| Desmopressin 240 mcg | Patients treated with desmopressin 240mcg Receives: Drug: Desmopressin lyophilisate (Melt) | |
| Desmopressin 240 mcg + anticholinergic | Patients treated with desmopressin 240mcg + anticholinergic agent Receives: Drug: Propiverine tablet |
What is being measured
The primary outcome is the main question the study is designed to answer.
Number of days without bedwetting
Achievement of bedwetting in one or less night of a month
Measured: 1 month
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted19 Jun 2025
- Study start20 Aug 2022
- Primary completion1 Sep 2024
- Study completion30 Dec 2025 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for Enuresis, NocturnalStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Retrospective
- Enrolment
- 100 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Furkan Adem Canbaz
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor-investigator, Furkan Adem Canbaz, Sehit Prof. Dr. Ilhan Varank Sancaktepe Training and Research Hospital
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07028645
- Sponsor's protocol ID
- Ivstrh - UF PMNE
- Status last verified
- Jun 2025
- First submitted
- 11 Jun 2025
- Last updated
- 24 Jun 2025
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- Yes
- FDA-regulated device
- No
- Individual data sharing
- Undecided
Publications
Kang BJ, Chung JM, Lee SD. Evaluation of Functional Bladder Capacity in Children with Nocturnal Enuresis According to Type and Treatment Outcome. Res Rep Urol. 2020 Sep 15;12:383-389. doi: 10.2147/RRU.S267417. eCollection 2020.
PubMed 32984086
Study at a glance
From the registry record, last updated by the sponsor on 24 Jun 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Is Uroflowmetry Useful in Assessing Response to Pharmacological Treatment in Enuresis
- ClinicalTrials.gov ID
- NCT07028645
- Acronym / sponsor ID
- Ivstrh - UF PMNE
- Conditions
- Enuresis, Nocturnal
- Keywords
- Uroflowmetry, Enuresis
- Study type
- Observational
- Recruitment status
- Active, not recruiting
- Enrolment
- 100 participants (estimated)
- Lead sponsor
- Furkan Adem CanbazUniversity, hospital or other
- Study start
- 20 Aug 2022 (actual)
- Primary completion
- 1 Sep 2024 (actual)
- Study completion
- 30 Dec 2025 (estimated)
- First posted
- 19 Jun 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This study will evaluate the uroflowmetry parameters of patients which were treated for enuresis.
Detailed description
A total of approximately 100 patients with enuresis will be evaluated retrospectively. Uroflowmetry parameters of these patients will be evaluated. For this purpose, patients will be divided to mainly three groups according to the treatment choices.
Study design
- Observational model
- Cohort
- Time perspective
- Retrospective
- Number of arms
- 3
| Arm | Type | Receives |
|---|---|---|
| Desmopressin 120mcg | – | Drug: desmopressin melt form 120 μgPatients treated with desmopressin 120 mcg |
| Desmopressin 240 mcg | – | Drug: Desmopressin lyophilisate (Melt)Patients treated with desmopressin 240mcg |
| Desmopressin 240 mcg + anticholinergic | – | Drug: Propiverine tabletPatients treated with desmopressin 240mcg + anticholinergic agent |
Who may qualify
- Ages
- 5 to 17 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Child
- Study population
- Patients who were treated for enuresis in pediatric urology clinic of Sancaktepe Sehit Prof Dr Ilhan Varank Training and Research Hospital
Key inclusion criteria (2 listed)
- Presence of enuresis nocturna
- Patients who have uroflowmetry test
Key exclusion criteria (3 listed)
- Presence of lower urinary tract symptoms
- Presence of anatomical or neurological problems
- Patients with missing data
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| desmopressin melt form 120 μgDesmopressin 120 mcg will be used frist-line drug in the treatment of enuresis. | Drug | Desmopressin 120mcg |
| Desmopressin lyophilisate (Melt)Desmopressin 240 mcg will be used for the patients who have not responsive to desmopressin 120 mcg. | Drug | Desmopressin 240 mcg |
| Propiverine tabletPropiverine (a dose of 0.8 mg/ kg) will be used for the patients who have -response to treatment with desmopressin 240 mcg | Drug | Desmopressin 240 mcg + anticholinergic |
Primary outcome
Number of days without bedwetting
Time frame: 1 month
Achievement of bedwetting in one or less night of a month
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 24 Jun 2025.
- Background: PubMed 32984086Kang BJ, Chung JM, Lee SD. Evaluation of Functional Bladder Capacity in Children with Nocturnal Enuresis According to Type and Treatment Outcome. Res Rep Urol. 2020 Sep 15;12:383-389. doi: 10.2147/RRU.S267417. eCollection 2020.
- Individual participant dataSharing planned: Undecided
Related trials for Enuresis, Nocturnal
Recruiting
Effectiveness of Individualized Pelvic Floor Muscle Rehabilitation in Addition to Standard Urotherapy and Alarm Therapy in Children With Primary Monosymptomatic Nocturnal Enuresis
Primary Monosymptomatic Nocturnal Enuresis
Active, not recruitingPhase 3
Autologous Muscle Derived Cells Compared to Placebo for Urinary Sphincter Repair in Post-surgical Female Stress Incontinence
Stress Urinary Incontinence
Not yet recruiting
Potential Adjuvant Therapies for Children With Primary Nocturnal Enuresis
Nocturnal Enuresis in Children, Primary Nocturnal Enuresis
Active, not recruitingPhase 3
Efficacy of Mirabegron for Treatment of Non-monosymptomatic Nocturnal Enuresis in Children
Treatment of Non-monosymptomatic Nocturnal Enuresis
Recruiting
Adjustable Continence Therapy (ACT) for the Treatment of Female SUI
Urinary Incontinence, Urinary Incontinence,Stress
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Enuresis, Nocturnal, run by Furkan Adem Canbaz at 1 site in Turkey (Türkiye).
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 2 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: under way, not looking for participants, as of the sponsor's last update on 24 Jun 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Turkey (Türkiye). Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Number of days without bedwetting (time frame: 1 month). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT07028645, which also lists 1 linked publication.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 24 Jun 2025.